Anti-inflammatory therapy for diabetic retinopathy

Wenbo Zhang, Hua Liu, Modesto Rojas, Robert W. Caldwell, Ruth B. Caldwell

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Diabetic retinopathy (DR) is one of the most common complications of diabetes. This devastating disease is a leading cause of blindness in people of working age in industrialized countries and affects the daily lives of millions of people. Despite tight glycemic control, blood pressure control and lipid-lowering therapy, the number of DR patients keeps growing and therapeutic approaches are limited. Moreover, there are significant limitations and side effects associated with the current therapies. Thus, there is a great need for development of new strategies for prevention and treatment of DR. Studies have shown that DR has prominent features of chronic, subclinical inflammation. This article focuses on the role of inflammation in DR and summarizes the progress of studies of anti-inflammatory strategies for DR.

Original languageEnglish (US)
Pages (from-to)609-628
Number of pages20
JournalImmunotherapy
Volume3
Issue number5
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Anti-Inflammatory Agents
Therapeutics
Inflammation
Diabetes Complications
Blindness
Developed Countries
Blood Pressure
Lipids

Keywords

  • diabetic retinopathy
  • inflammation
  • leukostasis
  • neovascularization
  • NF-κB
  • nitric oxide
  • oxidative stress
  • vessel degeneration
  • vessel leakage

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Anti-inflammatory therapy for diabetic retinopathy. / Zhang, Wenbo; Liu, Hua; Rojas, Modesto; Caldwell, Robert W.; Caldwell, Ruth B.

In: Immunotherapy, Vol. 3, No. 5, 05.2011, p. 609-628.

Research output: Contribution to journalArticle

Zhang, W, Liu, H, Rojas, M, Caldwell, RW & Caldwell, RB 2011, 'Anti-inflammatory therapy for diabetic retinopathy', Immunotherapy, vol. 3, no. 5, pp. 609-628. https://doi.org/10.2217/imt.11.24
Zhang, Wenbo ; Liu, Hua ; Rojas, Modesto ; Caldwell, Robert W. ; Caldwell, Ruth B. / Anti-inflammatory therapy for diabetic retinopathy. In: Immunotherapy. 2011 ; Vol. 3, No. 5. pp. 609-628.
@article{0e91f0242d934d23ace611bb97f63a16,
title = "Anti-inflammatory therapy for diabetic retinopathy",
abstract = "Diabetic retinopathy (DR) is one of the most common complications of diabetes. This devastating disease is a leading cause of blindness in people of working age in industrialized countries and affects the daily lives of millions of people. Despite tight glycemic control, blood pressure control and lipid-lowering therapy, the number of DR patients keeps growing and therapeutic approaches are limited. Moreover, there are significant limitations and side effects associated with the current therapies. Thus, there is a great need for development of new strategies for prevention and treatment of DR. Studies have shown that DR has prominent features of chronic, subclinical inflammation. This article focuses on the role of inflammation in DR and summarizes the progress of studies of anti-inflammatory strategies for DR.",
keywords = "diabetic retinopathy, inflammation, leukostasis, neovascularization, NF-κB, nitric oxide, oxidative stress, vessel degeneration, vessel leakage",
author = "Wenbo Zhang and Hua Liu and Modesto Rojas and Caldwell, {Robert W.} and Caldwell, {Ruth B.}",
year = "2011",
month = "5",
doi = "10.2217/imt.11.24",
language = "English (US)",
volume = "3",
pages = "609--628",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Anti-inflammatory therapy for diabetic retinopathy

AU - Zhang, Wenbo

AU - Liu, Hua

AU - Rojas, Modesto

AU - Caldwell, Robert W.

AU - Caldwell, Ruth B.

PY - 2011/5

Y1 - 2011/5

N2 - Diabetic retinopathy (DR) is one of the most common complications of diabetes. This devastating disease is a leading cause of blindness in people of working age in industrialized countries and affects the daily lives of millions of people. Despite tight glycemic control, blood pressure control and lipid-lowering therapy, the number of DR patients keeps growing and therapeutic approaches are limited. Moreover, there are significant limitations and side effects associated with the current therapies. Thus, there is a great need for development of new strategies for prevention and treatment of DR. Studies have shown that DR has prominent features of chronic, subclinical inflammation. This article focuses on the role of inflammation in DR and summarizes the progress of studies of anti-inflammatory strategies for DR.

AB - Diabetic retinopathy (DR) is one of the most common complications of diabetes. This devastating disease is a leading cause of blindness in people of working age in industrialized countries and affects the daily lives of millions of people. Despite tight glycemic control, blood pressure control and lipid-lowering therapy, the number of DR patients keeps growing and therapeutic approaches are limited. Moreover, there are significant limitations and side effects associated with the current therapies. Thus, there is a great need for development of new strategies for prevention and treatment of DR. Studies have shown that DR has prominent features of chronic, subclinical inflammation. This article focuses on the role of inflammation in DR and summarizes the progress of studies of anti-inflammatory strategies for DR.

KW - diabetic retinopathy

KW - inflammation

KW - leukostasis

KW - neovascularization

KW - NF-κB

KW - nitric oxide

KW - oxidative stress

KW - vessel degeneration

KW - vessel leakage

UR - http://www.scopus.com/inward/record.url?scp=79955912644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955912644&partnerID=8YFLogxK

U2 - 10.2217/imt.11.24

DO - 10.2217/imt.11.24

M3 - Article

VL - 3

SP - 609

EP - 628

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 5

ER -